During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and ...

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment ...

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Dax Kurbegov, MD, discusses findings from the CORE-HH study that build on growing evidence to support the clinical feasibility of blood-based early detection tools.

The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ...

Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...